Topper Copies

Dr. Mehra is a senior drug developer at a leading pharmaceutical company in India, renowned for producing various medications, including lifesaving drugs critical for treating chronic and rare diseases. Since its inception, the company has emphasized the quality and affordability of its drugs. Recently, under revised government guidelines, pharmaceutical companies are required to market a finished product only after obtaining "satisfactory results" from tests on the ingredients. Additionally, they must retain a sufficient quantity of samples of both intermediate and final products to allow repeated testing or verification of a batch. Dr. Mehra's team is in the final stages of developing a new medication for a rare but life-threatening disease. This drug has shown promising results in clinical trials. However, there have been unresolved concerns about the long-term side effects of the drug, observed in a small percentage of trial subjects. Despite this, the company has not released any major drug in the past decade, leading to significant pressure from the board members to expedite the drug's release. (a) Identify the stakeholders in the above case study. (b) Discuss the ethical issues faced by Dr. Mehra. (c) Analyse the options available to Dr. Mehra in the above case. Which of these would you choose and why?

Simrandeep Kaur, AIR 15, 2025

This case showcase medical ethical dilemmas of clinical trials. There were similar debates on TTS vulnerability caused by Astrazeneca's COVID Vaccine recently.

b) Ethical Issues faced by Dr. Mehra

1. Long term intangible asset of the Company:- Quality of Drugs 2. Rule of Law by showing transparency in all side effects. 3. Profits (recouping of Research cost) by releasing drugs. 4. Obeying orders of Hierarchy 5. Many v/s Few dilemma: life saving drug v/s side effects in long run.

c) Options available to Dr. Mehra

1. Release the drug along with transparent recognition of possible long term effects Merits - Profit maximization - Transparency and Accountability

Demerits - Govt. may ban it - Board members may disapprove transparency.

2) Conduct more research in drugs to remove any side-effect Merits - Rule of law - Reputation of Company - life Saving

Demerits - Cost burdens for a rare disease - disapproval chances from board members.

3) Release the drug (opaquely) Merits - Professional growth - less long term side effects (unnoticed)

Demerits - Violation of Public Trust on quality of Company - will hurt Conscience of Dr. Mehra.

I would choose option (2) for Dr. Mehra:- Conduct more research on drug & remove any side effects

- This will give ethical relief to Dr. Mehra for his virtue ethics. - For company, this will increase long term reputation and public trust. - Right to dignified life of citizens. (Kantian moral ethics).

It is rightly said,

"Business can't be successful if society around them fail"